Ileal Bile Acid Transporter Inhibitor Drug Class List

Drugs in Drug Class: Ileal Bile Acid Transporter Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662-001	Sep 29, 2021		RX	Yes	Yes	11,229,647
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662-002	Jul 24, 2024		RX	Yes	Yes
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-002	Apr 10, 2025		RX	Yes	No	10,512,657
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-004	Apr 10, 2025		RX	Yes	Yes	11,376,251
Mirum	LIVMARLI	maralixibat chloride	SOLUTION;ORAL	214662-001	Sep 29, 2021		RX	Yes	Yes
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-001	Apr 10, 2025		RX	Yes	No	12,350,267
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-003	Apr 10, 2025		RX	Yes	No	11,229,661

Market Dynamics and Patent Landscape for Ileal Bile Acid Transporter (IBAT) Inhibitor Drugs

Last updated: April 25, 2026

What defines the IBAT inhibitor market and how does it move?

Ileal bile acid transporter inhibitors (IBAT inhibitors) block the apical bile acid reuptake transporter in the terminal ileum (commonly referenced as ASBT/SLC10A2). The therapeutic thesis is to reduce enterohepatic bile acid recycling, increase bile acid loss in feces, and shift bile acid pools, which can affect cholesterol metabolism, hepatic bile acid synthesis, and metabolic and gastrointestinal downstream pathways.

Core commercial drivers

• Geography and formulary access: Most IBAT inhibitor programs target metabolic and cholestatic-adjacent indications where payer positioning and step therapy shape early uptake.
• Route to differentiations: Companies compete on dose frequency, patient-reported GI tolerability, and predictable bile acid exposure (less variability reduces discontinuations and supports tighter labeling).
• Label breadth and combination strategy: Market share depends on whether products win expanded indication language and whether they can be paired with statins, ezetimibe, bile acid sequestrants, or metabolic agents without new safety friction.

Demand pockets by indication archetype

IBAT inhibitor commercial demand clusters around:

• Dyslipidemia / cardiovascular risk modification where bile acid pool alteration changes LDL-C and related biomarkers.
• Cholestatic disorders and bile acid malabsorption-adjacent syndromes where bile acid handling drives symptom burden and liver indices.
• Metabolic and GI symptoms linked to bile acid physiology, where payers evaluate both clinical endpoints and discontinuation rates.

Which drugs and candidates anchor today’s IBAT inhibitor patent landscape?

The global IBAT inhibitor landscape is concentrated around a small number of molecules. The most visible commercial entrant in the class is maralixibat (Liver class and cholestatic indications; also discussed across dysmetabolic bile acid pathways). Other IBAT inhibitors include elobixibat (approved in Japan for constipation-predominant IBS and related constipation indications) and other investigational IBAT-directed assets, but the patent landscape differs materially by molecule and geography.

Because the patent landscape is molecule-specific, market dynamics tie directly to:

• Primary composition-of-matter families
• Salt/solid-state and polymorph families
• Formulation/device IP
• Use and method-of-treatment claims by specific indication or patient population

How do IBAT inhibitors price and get reimbursed, and what does the IP do to it?

Pricing and reimbursement pattern (class-level)

IBAT inhibitors face payer scrutiny for tolerability and chronic-use economics. The reimbursement pathway is strongly influenced by:

• GI adverse events (diarrhea, abdominal pain) that can trigger step edits and adherence loss.
• Measurable biochemical endpoints accepted by payers (LDL-C reduction, bile acid indices, liver biochemistry where relevant).
• Comparative effectiveness claims against existing standard-of-care (SOC): bile acid sequestrants, statins/ezetimibe, and supportive cholestasis regimens.

How patent terms translate to market control

For IBAT inhibitors, the value protection stack usually sits on three pillars:

1. Composition-of-matter (MoA-independent)
2. Formulation and solid-state (tablet properties, dissolution, and GI tolerability)
3. Method-of-treatment claims (indication-specific)

When early MoA patents are narrow, companies lean harder on secondary IP (polymorphs, controlled-release formulations, and specific dosing regimens).

What is the patent landscape for IBAT inhibitors, by molecule?

Maralixibat (IBAT inhibitor)

Maralixibat is the dominant reference molecule for IBAT inhibitor market valuation tied to cholestatic and bile acid handling indications.

IP coverage patterns (how protection typically manifests)

• Core MoA compound families spanning multiple jurisdictions using continuation and divisional strategies
• Salt/solid-state protection to extend exclusivity where regulators accept new polymorph or formulation changes
• Use claims that map to specific patient populations and regimen endpoints

Market relevance of maralixibat IP

Maralixibat’s market control depends less on generic competition timelines alone and more on whether secondary patents block:

• Tablet/capsule forms used in commercial supply
• Titration regimens and dose modifications that drive tolerability
• Indication-specific endpoints used in prescribing information

Elobixibat (IBAT inhibitor)

Elobixibat is an IBAT inhibitor with established commercial use in Japan in constipation-related indications, making it a key reference point for IP and lifecycle management outside North America.

IP coverage patterns

• Early compound families plus localized protection for the approved indication and formulation
• Japan and EMA-level enforcement differs; product enforcement often relies on how local regulators list the approved salt form and dosing regimen

Market relevance of elobixibat IP

For investors, elobixibat demonstrates that:

• GI tolerability becomes central to persistence in chronic constipation-related use.
• Local market exclusivity often hinges on whether method-of-treatment claims remain enforceable after generic entry.

Investigational IBAT inhibitors

Multiple next-generation IBAT inhibitors appear in pipelines, but their patent landscape differs by:

• Whether they claim a new chemical entity (broad MoA claims) versus improved selectivity or route
• Whether they secure solid-state exclusivity in regions where generics can copy earlier forms

Because IBAT inhibitors have a compact target space, incremental molecules often fight for patent term by pairing:

• MoA-level selectivity
• PK/PD-based dosing rationale
• Specific formulation parameters

What are the key patent threat points that can shorten exclusivity?

1) Generic “formulation design-around”

Even when the composition-of-matter claims hold, generics can:

• Move to alternative salts/polymorphs
• Change excipient system or release profile
• Alter dosing shape to avoid infringement on formulation-dependent claims

2) Narrow method-of-treatment claims

If method claims specify tight endpoints or diagnostic criteria, generic challengers can:

• Target broader indication language or different patient cohorts
• Argue non-infringement due to label-limited use patterns

3) Patent term fragmentation across jurisdictions

IBAT inhibitor assets often have:

• Earlier filing dates in some jurisdictions
• Later continuation filings in others
• Different claim scopes per office This creates patchy exclusivity and shifts market entry timing from the “headline” global end date.

How does competition shape pricing and prescribing behavior in IBAT inhibitors?

Competitive set dynamics

In practical market access:

• Statin/ezetimibe sits outside IBAT’s direct MoA, so payers may accept IBAT as add-on or alternative where endpoints are distinct.
• Bile acid sequestrants compete on bile acid handling but differ by GI tolerability and dosing complexity. If sequestrants dominate cost-minimization, IBAT uptake depends on tolerability and endpoint credibility.
• Cholestasis supportive treatments compete through clinician preference and liver monitoring pathways.

Prescribing behavior

Titration and discontinuation rates typically determine real-world sales. That makes IP on:

• Dose titration steps
• Tablet dissolution profile
• Clinical monitoring schedules a commercial lever, not just a legal one.

What does the patent landscape imply for market entry timing and risk?

How to read patent risk for IBAT inhibitors

A buyer/investor lens focuses on:

• Earliest priority date for composition-of-matter
• Jurisdictional grant status and claim breadth
• Secondary patent families that track:
  • formulation,
  • solid-state forms,
  • dosing regimens,
  • specific indication claims

Typical outcome pathways

• If a company has strong secondary formulation protection, generic entry is delayed even after headline MoA expiration.
• If secondary patents are weak or non-overlapping, the market is exposed to faster generic erosion.

Key product and IP feature map (investment-grade snapshot)

Segment	What wins	What blocks generics	Market signal to watch
Cholestatic/bile acid handling	Sustained tolerability and lab response	Solid-state and titration-regimen claims	Discontinuation rates in claims data
Dyslipidemia-adjacent	Endpoint strength that payers accept	Indication-specific method claims	Formulary tier placement and step therapy
Chronic constipation-related	Stool quality and adherence	Formulation-based IP in local markets	Persistence curves by cohort

Key Takeaways

• IBAT inhibitors are a concentrated class where market control depends on secondary patent layers (formulation, solid-state, titration regimens, and indication-specific method claims), not just composition-of-matter.
• Market adoption hinges on GI tolerability and payer-accepted endpoints, which in turn drives how enforceable method claims and formulation-dependent claims need to be.
• Patent threat is primarily design-around (salt/polymorph/release profile) and label/narrow claim non-infringement rather than direct MoA-level invalidation alone.
• For maralixibat and other anchor molecules, investor and R&D planning should track jurisdictional claim scope and grant timing plus formulation IP that can withstand generic design-around.

FAQs

1) What is the core MoA of IBAT inhibitors?
They inhibit the ileal bile acid reuptake transporter (ASBT/SLC10A2), reducing enterohepatic bile acid recycling and shifting bile acid physiology.

2) Why do formulation and solid-state patents matter in IBAT inhibitors?
IBAT inhibitors have dosing- and tolerability-linked performance; changing salt/polymorph or release behavior can be a practical generic design-around.

3) What patent types most affect generic entry risk?
Composition-of-matter is foundational, but formulation, solid-state, and indication-specific method-of-treatment claims often determine real-world exclusivity.

4) How do payers evaluate IBAT inhibitors?
They prioritize tolerability (especially GI events) and biochemical or clinical endpoints that align with label and coverage policies.

5) What competitive forces most pressure IBAT pricing?
Existing SOC in dyslipidemia and bile acid handling (statins/ezetimibe and bile acid sequestrants) plus payer step edits tied to adherence and discontinuation.

---

References

[1] United States Patent and Trademark Office. Patent Public Search and related database resources. https://ppubs.uspto.gov/
[2] European Patent Office. Espacenet patent information and document access. https://worldwide.espacenet.com/
[3] WIPO. PATENTSCOPE search for published patent applications. https://patentscope.wipo.int/